TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00560612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: same as paroxetine (active comparator)
Study: NCT04241458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 703621
Description: BI 703621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT02051881

Intervention type: OTHER
Group type: OTHER
Intervention: Taking intestinal biopsies
Study: NCT03327896

Intervention type: OTHER
Intervention: Charlson score and Community Social Deprivation
Description: This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
Study: NCT03477279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Couple HIV Testing and Counseling
Description: Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another.
Study: NCT01337557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine
Description: 1.5% bid
Study: NCT03138174

Intervention type: DEVICE
Intervention: OneTouch Verio Flex Blood Glucose Monitoring System
Description: Blood Glucose Monitoring System
Study: NCT02967614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]
Description: One eye drop(about 40ul) / Day1 \~ Day8 / BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [B]
Description: One eye drop(about 40ul) / Day1 \~ Day92 / BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]+[B](1)
Description: One eye drop(about 40ul) / Day9 \~ Day100 / BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]+[B](2)
Description: One eye drop(about 40ul) / Day93 \~ Day100 / BID
Study: NCT03811561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
Study: NCT02398968

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fumerate
Description: iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fumerate
Description: iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
Study: NCT02467270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Tablet, taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Tablet, taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Tablet, taken orally once daily.
Study: NCT00664937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast sodium
Description: single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast sodium
Description: single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast sodium
Description: single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: single oral dose, before exercise challenge, of Pbo; 7 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: single oral dose, before exercise challenge, of Pbo; 7 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: single oral dose, before exercise challenge, of Pbo; 7 week duration.
Study: NCT04837586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
Study: NCT03327896

Intervention type: OTHER
Intervention: Charlson score and Community Social Deprivation
Description: This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.

Intervention type: OTHER
Intervention: Charlson score and Community Social Deprivation
Description: This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.

Intervention type: OTHER
Intervention: Charlson score and Community Social Deprivation
Description: This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
Study: NCT00546390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Cuff
Description: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
Study: NCT02200900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal pressure
Description: Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal pressure
Description: Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide
Description: Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide
Description: Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal gas concentrations
Description: Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
Study: NCT04837586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Scale
Description: Individuals will be encouraged to perform daily weighing at home on a simple scale.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Connected Scale
Description: Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
Study: NCT03707951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Study: NCT01497405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)
Description: TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Test, Treat, Retain(TTR) only
Description: TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
Study: NCT03032172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally once daily.
Study: NCT04544410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study: NCT02200900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal gas concentrations
Description: Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume
Description: Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume
Description: Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
Study: NCT00642538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC253 Inhalation Powder
Description: Inhalation Powder, prandial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC253 Inhalation Powder
Description: Inhalation Powder, prandial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC253 Inhalation Powder
Description: Inhalation Powder, prandial
Study: NCT00764036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
Study: NCT02488343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
Study: NCT04610567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate-LDE phase 1
Description: 3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate-LDE phase 2
Description: 44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-LDE phase 2
Description: 44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
Study: NCT02727777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
Study: NCT00642538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Inhalation Powder
Description: Inhalation Powder, prandial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous injection
Description: 10µg Exenatide, prandial
Study: NCT03348215

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treadmill Training
Description: 6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
Study: NCT02727777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sugar Testing
Description: Participant given a glucometer to check pre-dose blood sugar levels at home every day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sugar Testing
Description: Participant given a glucometer to check pre-dose blood sugar levels at home every day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sugar Testing
Description: Participant given a glucometer to check pre-dose blood sugar levels at home every day.
Study: NCT00647738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Single-dose 20 mg immediate-release oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Single-dose 20 mg immediate-release oral tablet
Study: NCT00839813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 10 weeks of a trauma-sensitive yoga class
Study: NCT02776436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose of prophylactic dexamethasone will be reduced for all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose of prophylactic dexamethasone will be reduced for all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: standard prednisone 5 mg bid for patients with prostate cancer
Study: NCT03728426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day.
Study: NCT05581940

Intervention type: COMBINATION_PRODUCT
Intervention: Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors
Description: (CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.\[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
Study: NCT02489617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathologic evaluation of excised tissue
Description: Up to 3 months after excisional biopsy
Study: NCT03363464

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: dipeptidyl peptidase-4 inhibitor

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Glucagon-like peptide-1 receptor agonist
Study: NCT02231190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
Study: NCT03842371

Intervention type: OTHER
Intervention: Metabolic level of BCAAs in monocytes and macrophages
Description: Metabolic level of BCAAs in monocytes and macrophages

Intervention type: OTHER
Intervention: Metabolic level of BCAAs in monocytes and macrophages
Description: Metabolic level of BCAAs in monocytes and macrophages
Study: NCT01926613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking Skills for Work Program
Description: The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported Employment
Description: Supported Employment is an evidence based vocational rehabilitation program
Study: NCT04074200

Intervention type: PROCEDURE
Intervention: Open Inguinal Hernia Repair
Description: With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.

Intervention type: PROCEDURE
Intervention: Laparoscopic Inguinal Hernia Repair
Description: With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
Study: NCT04266587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood sampling is done on healthy volunteers
Study: NCT02698332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm for UTI
Description: The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
Study: NCT04074200

Intervention type: DEVICE
Intervention: Robotic-Assisted Inguinal Hernia Repair
Description: With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
Study: NCT04892784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press tack needle acupuncture
Description: Pyonex press tack needle sized 0.20x1.2mm
Study: NCT00423384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: I.v.
Study: NCT03842371

Intervention type: OTHER
Intervention: Metabolic level of BCAAs in monocytes and macrophages
Description: Metabolic level of BCAAs in monocytes and macrophages
Study: NCT02318498

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CMR
Description: Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CMR
Description: Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
Study: NCT02315898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment-inhaled tPA
Description: Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
Study: NCT02641613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retroclavicular block
Description: retroclavicular block for forearm or hand surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular block
Description: supraclavicular block for forearm or hand surgery